Radiation therapy (RT) resistance is a major challenge in the treatment of glioblastoma multiforme (GBM), which is largely related to DNA repair, poor distribution of reactive free radicals in the tumor, and limited delivery of radiosensitizers to the tumor site. Inspired by the abnormal upregulation of RAD51 (DNA repair key protein), scavenger receptor type B1 (SR-B1), and chemokine ligand 5 (CCL5) in GBM patients, Professor Sun Maoyuan's team at Chongqing Medical University synthesized a reduction sensitive nitric oxide (NO) donor conjugate of gemcitabine (RAD51 inhibitor) (NG) as a radiosensitizer and designed a CCL5 peptide modified NG biomimetic lipoprotein system (C-LNG) to preferentially target tumor sites and overcome RT resistance. C-LNG can preferentially accumulate at the site of in situ GBM tumors, with a certain degree of tumor permeability, responsive to the release of gemcitabine and NO. After X-ray irradiation, abundant peroxynitrite (ONOO −) is produced, resulting in 99.64% tumor growth inhibition and 71.44% survival rate in GL261 induced in situ GBM tumor models. Therefore, a well-designed NG biomimetic lipoprotein provides a necessary strategy for targeting GBM and overcoming RT resistance.
The study was published on November 4, 2023 in the international journal ADVANCED SCIENCE, titled "Bioinsined Lipoproteins of Furoxans – Gemcitabine Preferentially Targets Glioblastoma and Overcomes Radiotherapy Resistance".
IF=15.1。
Figure 1. The study was published in the international journal ADVANCED SCIENCE
Figure 2. Images in the article
Figure 3. Cell culture in this study was conducted using Opsey fetal bovine serum
https://onlinelibrary.wiley.com/doi/10.1002/advs.202306190